Virus Like Particles Market Will Escalate Rapidly In The Near Future, 2028Posted by Arianna Huffington on October 7th, 2022 Virus-Like Particles (VLP’s) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type (Hepatitis, Cancer/HPV, and Gaucher Disease), Source (Yeast, Insect Cell, Plants, and Others), Application (Vaccines, Therapeutics) Product Type Virus-Like Particles (VLP’s) Segment to Hold Largest Share of Virus-Like Particles (VLP’s) Market During 2021–2028 According to our latest study on “Virus-Like Particles (VLP’s) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Source, and Application,” the market is projected to reach US$ 7,858.82 million by 2028 from US$ 4,601.84 million in 2021; it is expected to grow at a CAGR of 7.9% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market. The outbreak of SARS-CoV-2 resulted in the COVID-19 pandemic, a severe acute respiratory syndrome, in 2020. The successful application of VLPs has brough improvements in vaccinology and virology studies. As VLPs based vaccines use platforms that are capable of producing particles that mimic the structure of authentic viruses and possess the inherent ability of antigenic proteins to self-assemble it can prove advantageous in the ongoing fight against COVID-19. According to a report by Frontiers S.A., there have been intensive studies involving mammalian expression systems for the construction of SARS-CoV-2 VLPs for vaccine production. Based on source, the virus-like particles (VLP’s) market is segmented into yeast, insect cell, plants, and others. The yeast segment held the largest share of the market in 2020 and is projected to continue a similar trend during the forecast period. On the other hand, the plant segment is estimated to register the highest CAGR in the market during the forecast period. The National Library of Medicine report states that there has been a remarkable achievement in the expression and assembly of VLPs and their chimeric derivatives in plant systems, as well as their immunogenicity in animal models. Recent success in the cultivation of humanized glycosylation plant cell lines and approval for the first plant-based biologics by the US Food and Drug Administration (FDA) signify promising prospects for the large-scale production and commercialization of VLP-based vaccines. Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Dynavax Technologies; Sanofi; Wantai BioPharm; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; and VBI Vaccines Inc.; are among the leading companies operating in the global virus-like particles (VLP’s) market.
The report segments the virus-like particles (VLP’s) market as follows: By Product Type
By Source
By Application
· By Geography
About The Insight Partners The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Healthcare, Media, and Telecommunication. Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis. Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, products, applications, end users, etc., which helps our clients to gain a deeper analytical understanding of various research topics. Contact Us If you have any queries about this report or would like further information, please contact us:
Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the publisher, “The Insight Partners”. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions, and recommendations that “The Insight Partners” delivers will be based on information gathered in good faith from primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, “The Insight Partners” can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect. Like it? Share it! More by this author |